Please provide your email address to receive an email when new articles are posted on . 10.5% of patients treated with isotretinoin experienced mood changes. 88% of patients experienced symptom ...

Cutia Therapeutics ( ($HK:2487) ) has shared an announcement. Cutia Therapeutics announced that a post-hoc analysis of their Phase III clinical ...

BRIDGEWATER, N.J., June 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing ...

Acne vulgaris is a multifactorial skin disorder marked by inflammatory and non-inflammatory lesions that can cause significant physical and psychological distress. Traditional treatment options, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A multi-center, prospective, open-label, single arm ...

Acne vulgaris is one of the commonest skin disorders, which dermatologists treat and it mainly affects adolescents, though it may appear at any age. Acne by definition is multifactorial chronic ...

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to severe acne vulgaris. ・The company said that once daily oral 50 mg Denifanstat ...

SAN DIEGO, Feb. 11, 2020 /PRNewswire/ -- Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial ...

SAN MATEO, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional ...

Active ingredients: Clindamycin (as phosphate) 1.2%, benzoyl peroxide 2.5%; gel. Indication: Topical treatment of acne vulgaris. Pharmacology: Acanya gel combines the lincosamide antibiotic, ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...